Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX9YLR)

• Drug Name: Pridopidine Drug Info
• Synonyms: PRIDOPIDINE; 346688-38-8; 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine; 4-(3-(Methylsulfonyl)phenyl)-1-propylpiperidine; ACR-16; UNII-HD4TW8S2VK; ACR16; ACR 16; HD4TW8S2VK; CHEMBL596802; FR310826; Pridopidine [USAN:INN]; Pridopidine (USAN/INN); 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine; SCHEMBL166748; CTK4H2809; DTXSID90188225; ASP 2314; ZINC22063703; BDBM50308028; AKOS015891431; DB11947; NCGC00386586-01; HY-10684; AS-50146; AJ-80925; FR 310826; DB-014417; AX8258340; CS-0002733; FT-0672149; Huntexil; Pridopidine hydrochloride; ASP-2314; Dopamine modulator (Huntingtons disease), Carlsson Research; Dopamine modulator (Huntingtons disease), NeuroSearch; Dopamine modulator (schizophrenia), Astellas; Dopamine modulator (schizophrenia), Fujisawa; Dopamine modulator (neurological disorders), Merck & Co

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9795739
  CAS Number: CAS 346688-38-8
  TTD Drug ID: DMX9YLR
  VARIDT Drug ID: DR00875

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[3]
Haloperidol	DM96SE0	Delirium		Approved	[4]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[5]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[6]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[7]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[8]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[9]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[10]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[11]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT00665223) A Study of Treatment With ACR16 in Patients With Huntington's Disease. U.S. National Institutes of Health.
• [2] Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4.
• [3] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [4] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [5] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [6] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [7] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [9] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [10] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [11] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [12] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.